Summary
38.45 0.24(0.62%)07/03/2024
Glaxosmithkline plc (GSK)
Glaxosmithkline plc (GSK)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.55 | -1.08 | -5.90 | -7.42 | -1.22 | 11.18 | 14.90 | 33,523.99 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 38.45 | |
| Open | 38.15 | |
| High | 38.49 | |
| Low | 38.13 | |
| Volume | 1,291,772 | |
| Change | 0.21 | |
| Change % | 0.55 | |
| Avg Volume (20 Days) | 3,253,925 | |
| Volume/Avg Volume (20 Days) Ratio | 0.40 | |
| 52 Week Range | 33.67 - 45.93 | |
| Price vs 52 Week High | -16.30% | |
| Price vs 52 Week Low | 14.18% | |
| Range | 0.77 | |
| Gap Up/Down | -0.17 | |
Fundamentals | ||
| Market Capitalization (Mln) | 77,911 | |
| EBIDTA | 10,536,999,936 | |
| PE Ratio | 16.5699 | |
| PEG Ratio | 1.0866 | |
| WallStreet Target Price | 45.79 | |
| Book Value | 3.3940 | |
| Earnings Per Share | 2.7200 | |
| EPS Estimate Current Quarter | 0.9100 | |
| EPS Estimate Next Quarter | 0.9400 | |
| EPS Estimate Current Year | 3.9900 | |
| EPS Estimate Next Year | 4.5500 | |
| Diluted EPS (TTM) | 2.7200 | |
| Revenues | ||
| Profit Marging | 0.1459 | |
| Operating Marging (TTM) | 0.3052 | |
| Return on asset (TTM) | 0.0932 | |
| Return on equity (TTM) | 0.3878 | |
| Revenue TTM | 30,740,000,768 | |
| Revenue per share TTM | 15.1500 | |
| Quarterly Revenue Growth (YOY) | 0.0590 | |
| Quarterly Earnings Growth (YOY) | -0.3040 | |
| Gross Profit (TTM) | 19,917,000,000 | |
| Dividends | ||
| Dividend Share | 0.5900 | |
| Dividend Yield | 0.0334 | |
| Valuations | ||
| Trailing PE | 16.5699 | |
| Forward PE | 10.3199 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.9647 | |
| Revenue Enterprise Value | 3.3190 | |
| EBITDA Enterprise Value | 11.0822 | |
| Shares | ||
| Shares Outstanding | 2,039,010,048 | |
| Shares Float | 3,930,906,540 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.06 | |
| Institutions (%) | 15.13 | |
07/03 13:46 EST - investopedia.com
GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
Drug maker GSK (GSK) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology company CureVac (CVAC).
GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
Drug maker GSK (GSK) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology company CureVac (CVAC).
07/03 10:18 EST - barrons.com
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
07/03 07:59 EST - forbes.com
GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech soaring during premarket trading and strengthening the British drugmaker's vaccine portfolio as it tries to compete with the likes of Moderna, Pfizer and BioNTech.
GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech soaring during premarket trading and strengthening the British drugmaker's vaccine portfolio as it tries to compete with the likes of Moderna, Pfizer and BioNTech.
07/03 07:53 EST - marketwatch.com
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vaccines.
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vaccines.
07/03 05:21 EST - fool.com
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
For investors with a long-term mindset, there's never a wrong time to put your money to work on Wall Street. Most online brokers have eliminated minimum deposit requirements and commission fees for common stock trades.
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
For investors with a long-term mindset, there's never a wrong time to put your money to work on Wall Street. Most online brokers have eliminated minimum deposit requirements and commission fees for common stock trades.
07/03 03:11 EST - proactiveinvestors.co.uk
GSK takes full control of flu vaccine programme in €1.45bn deal
GSK PLC (LSE:GSK, NYSE:GSK) said it will take effective control of a collaboration to create new mRNA vaccines for influenza and COVID-19 under a €1.45 billion deal. Under a new agreement with Germany's CureVac, the UK drugs giant will be ceded the rights to develop, manufacture, and sell these vaccines generated by the partnership.
GSK takes full control of flu vaccine programme in €1.45bn deal
GSK PLC (LSE:GSK, NYSE:GSK) said it will take effective control of a collaboration to create new mRNA vaccines for influenza and COVID-19 under a €1.45 billion deal. Under a new agreement with Germany's CureVac, the UK drugs giant will be ceded the rights to develop, manufacture, and sell these vaccines generated by the partnership.
07/03 02:40 EST - accesswire.com
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced LONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced LONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.
07/03 02:26 EST - reuters.com
GSK buys full rights to make COVID, influenza vaccines from CureVac
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.
GSK buys full rights to make COVID, influenza vaccines from CureVac
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.
06/28 12:20 EST - zacks.com
CDC Narrows Age Recommendation for Use of RSV Vaccine
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
CDC Narrows Age Recommendation for Use of RSV Vaccine
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
06/27 13:14 EST - investorplace.com
You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.
The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.
You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.
The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.
06/27 10:48 EST - schaeffersresearch.com
Biotech Stock Slips on CDC Buzz
British biotech stock GSK plc (NYSE:GSK) is trading lower, though it pared its steeper losses today, down 1% at $38.49 at last glance after earlier sliding as much as 7%.
Biotech Stock Slips on CDC Buzz
British biotech stock GSK plc (NYSE:GSK) is trading lower, though it pared its steeper losses today, down 1% at $38.49 at last glance after earlier sliding as much as 7%.
06/27 10:40 EST - zacks.com
Here's Why GSK (GSK) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why GSK (GSK) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
06/27 04:00 EST - proactiveinvestors.co.uk
GSK and Moderna slide on RSV vaccine CDC updates
GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine. Pfizer and Moderna, which also make RSV vaccines, fell 2% and 11% in New York overnight.
GSK and Moderna slide on RSV vaccine CDC updates
GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine. Pfizer and Moderna, which also make RSV vaccines, fell 2% and 11% in New York overnight.
06/27 03:58 EST - marketwatch.com
GSK stock falls more at London open following RSV vaccination news
GSK's London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.
GSK stock falls more at London open following RSV vaccination news
GSK's London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.
06/27 03:40 EST - proactiveinvestors.co.uk
GSK plummets as US restricts RSV vaccine
GSK PLC (LSE:GSK, NYSE:GSK) is attempting to drive the FTSE 100 lower after it plunged close to 7% following a ruling in the US that restricted the use of its RSV vaccine. The US Advisor Committee on Immunisation Practises announced all those over the age of 75 should only have a single dose of the treatment.
GSK plummets as US restricts RSV vaccine
GSK PLC (LSE:GSK, NYSE:GSK) is attempting to drive the FTSE 100 lower after it plunged close to 7% following a ruling in the US that restricted the use of its RSV vaccine. The US Advisor Committee on Immunisation Practises announced all those over the age of 75 should only have a single dose of the treatment.
06/27 03:40 EST - reuters.com
GSK slides 6% after US CDC narrows scope of RSV shots
GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending their use for those under 60 years of age.
GSK slides 6% after US CDC narrows scope of RSV shots
GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending their use for those under 60 years of age.
06/26 16:29 EST - marketwatch.com
Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations
Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.
Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations
Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.
06/26 06:13 EST - reuters.com
US advisers to consider RSV shots as GSK looks to keep market lead
A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.
US advisers to consider RSV shots as GSK looks to keep market lead
A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.
06/24 10:40 EST - zacks.com
GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance
The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.
GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance
The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.
06/24 09:55 EST - zacks.com
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.